We’re improving the lives of patients with rare cancers. 

Hillstream BioPharma is a development-stage company advancing improved therapies for patients with cancer.

Hillstream BioPharma is a development-stage company advancing improved therapies for patients with cancer.

Hillstream BioPharma is developing novel immune-oncology therapeutics for critical unmet needs. By harnessing the body's immune system and Hillstream’s proprietary QUATRAMER technology which reduces off-target effects, we are developing targeted cancer therapies with improved safety, delivery profile with higher efficacy. The competitive advantage results from the oncology therapies being encapsulated in the proprietary drug delivery QUATRAMER, a non-viral tumor infiltrating enhanced injectable suspension comprised of FDA-recognized inactive ingredients. Encapsulation ensures delivery within the tumor cells and prevents free drug levels in circulation that can cause toxicity. The slow and sustained release of the therapy may also reduce the frequency of dosing while maintaining its efficacy. The novel formulation allows Hillstream to build a strong patent estate and seek FDA Orphan Designation in specific indications.

Hillstream's QUATRAMER formulations of salinomycin (HSB-1216), tumor necrosis factor-alpha (HSB- 114), bortezomib (HSB-407), are currently in preclinical development for cancers with significant unmet need. In addition, Hillstream BioPharma has a CRADA with National Center for Advancing Translational Sciences (NCATS) for use of QUATRAMER drug delivery to develop specific and selective HDACC6-PI3Kδ dual inhibitor.

HSB-1216

First in class, highly potent small molecule cancer stem cell (CSC) inhibitor encapsulated in QUATRAMER nanoparticle for targeted delivery into tumors.

HSB-114

Next generation of human tumor necrosis factor- alpha gene for intratumoral delivery in soft tissue sarcoma.

HSB-501

Specific and selective HDAC6-PI3Kδ dual inhibitor for rare cancers with significant unmet medical need.

HSB-407

Nanoparticle formulation of FDA-approved bortezomib for the treatment of multiple myeloma, a rare cancer with significant unmet need.

Hillstream is this Month’s Recipient of BioNJ's Emerging Company in the Spotlight